You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. AXSOME THERAPEUTICS INC

Axsome Therapeutics Inc XNAS: AXSM

Axsome Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Momentum Trap
Download real time

103.91 0.91 (0.88%)

25.31% Fall from 52W High

541.2K XNAS Volume

XNAS 22 Apr, 2025 3:10 PM (EDT)

Watchlist

Portfolio

Share

Axsome Therapeutics Inc Key Metrics

Default

Market Capitalization

High in industry
5,067.2

PE TTM

Negative PE TTM
-17.6

PEG TTM

High in industry
0.9

Price to Book

High in industry
88.9

Institutional holding current Qtr %

Below industry Median
79.3

Revenue Growth Qtr YoY %

Below industry Median
66

Operating Revenue growth TTM %

Below industry Median
42.5

Net Profit Qtr Growth YoY %

Below industry Median
24.1

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-20.1

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-51.9

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-65.5

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

8.7

ROE Annual %

Negative ROE Annual %
-231.6

RoA Annual %

Negative RoA Annual %
-49.7
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
22.2 / 100
Valuation Score
Expensive Valuation
5.2 / 100
Momentum Score
Technically Neutral
55.1 / 100
Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
177
1Yr Price target upside is 71%
17 analysts

16

S

10

W

6

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Axsome Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '2601k2kActual RevenueAvg. Estimate
Hit

Axsome Therapeutics Inc's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

Current EPS
-6
Avg. Estimate
-3.3
Low Estimate
-4.9
High Estimate
-0.7
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 44.4% in FY25

Consensus Recommendation

18 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.25Buy13Strong Buy

The consensus recommendation from 18 analysts for Axsome Therapeutics Inc is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Axsome Therapeutics Inc Stock Analysis

Axsome Therapeutics Inc stock analysis with key metrics, changes, and trends.

Axsome Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$385.69 M42.53%positive

Annual Revenue rose 42.53%, in the last year to $385.69 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit$287.22 M20.05%negative

Annual Net Profit fell 20.05% in the last year to $287.22 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-17.64-negative

Price to Earning Ratio is -17.64, which is negative.

Stock Price$103.9153.03%positive

Stock Price rose 53.03% and outperformed its sector by 44.12% in the past year.

Quarterly Revenue$118.77 M66.04%positive

Quarterly Revenue rose 66.04% YoY to $118.77 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit$74.91 M24.06%positive

Quarterly Net profit rose 24.06% YoY to $74.91 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio3.38-negative

Debt to Equity Ratio of 3.38 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE)-231.63 %-231.63%negative

Return on Equity(ROE) for the last financial year was -231.63%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding44.59 %0.54%positive

Mutual Fund Holding increased by 0.54% in the last quarter to 44.59.

Promoter Share Holding0.66 %0.03%positive

Promoter Share Holding increased by 0.03% in the most recent quarter to 0.66%.

Interest Coverage Ratio-42.71-negative

Interest Coverage Ratio is -42.71, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding79.30 %1.33%positive

Institutional Holding increased by 1.33% in the last quarter to 79.3.

VIEW LESS


Loading data..

Axsome Therapeutics Inc - Company Profile

What does Axsome Therapeutics Inc do?

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Inc Management structure

All Gross Remunerations are in USD
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Nick Pizzie
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year

Axsome Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. Mark E. Saad
Independent Director
-
2024
Gross Remuneration
Year
Dr. Roger A. Jeffs, PhD
Lead Independent Director
-
2024
Gross Remuneration
Year
Dr. Susan Mahony, M.B.A.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President and Chief Executi
-
2024
Gross Remuneration
Year
Dr. Mark Coleman, M.D.
Independent Director
-
2024
Gross Remuneration
Year

Axsome Therapeutics Inc FAQ

How is Axsome Therapeutics Inc today?
Axsome Therapeutics Inc today is trading in the green, and is up by 0.88% at 103.91.
Axsome Therapeutics Inc is currently trading up 0.88% on an intraday basis. In the past week the stock rose 0.37%. stock has been up 8.04% in the past quarter and rose 53.03% in the past year. You can view this in the overview section.